The author says they found no flaw in retatrutide's phase 3 numbers and argues the strength of the results is itself the problem. The full reasoning is cut off.
Recap by typeshit. Post by Facebook on Facebook.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
Medical Xpress reports the weekly experimental drug beat placebo, which cut about 10 pauses per hour, in people with sleep apnea.
The writer ties together Nebraska compounding data, a pediatric obesity review and a report on online retatrutide that tested at half to double the labeled dose.
Loading…